Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1974 1
1977 2
1978 1
1979 2
1980 2
1981 2
1982 3
1983 1
1985 2
1986 2
1987 4
1990 1
1992 1
1993 2
1994 2
1995 2
1996 1
1997 3
1998 7
1999 5
2000 5
2001 7
2002 6
2003 3
2004 2
2005 5
2006 3
2007 2
2008 4
2009 4
2010 4
2011 2
2012 2
2013 1
2014 3
2015 3
2016 2
2017 4
2018 4
2019 5
2020 11
2021 10
2022 16
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Results by year

Filters applied: . Clear all
Page 1
DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models.
Yamato M, Hasegawa J, Maejima T, Hattori C, Kumagai K, Watanabe A, Nishiya Y, Shibutani T, Aida T, Hayakawa I, Nakada T, Abe Y, Agatsuma T. Yamato M, et al. Among authors: nishiya y. Mol Cancer Ther. 2022 Apr 1;21(4):635-646. doi: 10.1158/1535-7163.MCT-21-0554. Mol Cancer Ther. 2022. PMID: 35149548 Free PMC article.
The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.
Kaneda A, Seike T, Danjo T, Nakajima T, Otsubo N, Yamaguchi D, Tsuji Y, Hamaguchi K, Yasunaga M, Nishiya Y, Suzuki M, Saito JI, Yatsunami R, Nakamura S, Sekido Y, Mori K. Kaneda A, et al. Among authors: nishiya y. Am J Cancer Res. 2020 Dec 1;10(12):4399-4415. eCollection 2020. Am J Cancer Res. 2020. PMID: 33415007 Free PMC article.
Neprilysin Inhibitor May Increase Urinary C-Peptide Excretion.
Nishiya Y, Daimon M, Mizushiri S, Yanagimachi M, Tanabe J, Matsuki K, Sato E, Matsumura K. Nishiya Y, et al. Diabetes Care. 2022 Aug 1;45(8):e122-e123. doi: 10.2337/dc22-0538. Diabetes Care. 2022. PMID: 35713575 No abstract available.
Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models.
Suzuki H, Nagase S, Saito C, Takatsuka A, Nagata M, Honda K, Kaneda Y, Nishiya Y, Honda T, Ishizaka T, Nakamura K, Nakada T, Abe Y, Agatsuma T. Suzuki H, et al. Among authors: nishiya y. Mol Cancer Ther. 2024 Mar 4;23(3):257-271. doi: 10.1158/1535-7163.MCT-23-0287. Mol Cancer Ther. 2024. PMID: 38205802 Free PMC article.
Effects of sodium-glucose co-transporter 2 inhibitors on ultrafiltration in patients with peritoneal dialysis: a protocol for a randomized, double-blind, placebo-controlled, crossover trial (EMPOWERED).
Doi Y, Shinzawa M, Arisato T, Oka H, Matsumoto A, Kitamura H, Nakazono Y, Nishiya Y, Ueda Y, Kamimura T, Hayashi T, Yoshihara F, Isaka Y. Doi Y, et al. Among authors: nishiya y. Clin Exp Nephrol. 2024 Feb 25. doi: 10.1007/s10157-024-02467-w. Online ahead of print. Clin Exp Nephrol. 2024. PMID: 38402502
153 results